Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

Clinical Infectious Diseases

Volumn 52, Issue 3, 2011, Pages

  Liu, Catherine ^a   Bayer, Arnold ^c,e   Cosgrove, Sara E ^f   Daum, Robert S ^g   Fridkin, Scott K ^h   Gorwitz, Rachel J ^h   Kaplan, Sheldon L ⁱ   Karchmer, Adolf W ^j   Levine, Donald P ^k   Murray, Barbara E ^m   Rybak, Michael J ^k,l   Talan, David A ^d,e   Chambers, Henry F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l WAYNE STATE UNIVERSITY   (United States)

^m UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFAZOLIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LINEZOLID; MINOCYCLINE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BRAIN ABSCESS; CAVERNOUS SINUS THROMBOSIS; CELLULITIS; CEREBRAL SINUS THROMBOSIS; DEBRIDEMENT; DEVICE INFECTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ECZEMA; ENVIRONMENTAL SANITATION; EPIDURAL ABSCESS; ERYTHROCYTE SEDIMENTATION RATE; HEART VALVE PROSTHESIS; HUMAN; IMPETIGO; INTENSIVE CARE UNIT; LACERATION; MEDICAL SOCIETY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEONATAL PUSTULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PERSONAL HYGIENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN ULCER; SUBDURAL EMPYEMA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; WOUND DRAINAGE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; UNITED STATES; VANCOMYCIN; YOUNG ADULT;

EID: 79951844269     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq146     Document Type: Article

References (371)

1. Calfee DP, Salgado CD, Classen D, et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1): S62-S80.
2. Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1): S51-S61.
3. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
4. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7.
5. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71. (Pubitemid 47598444)
6. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8. (Pubitemid 28110205)
7. Liu C, Graber CJ, Karr M, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis 2008;46:1637-46. (Pubitemid 351706759)
8. D'Agata EM, Webb GF, Horn MA, et al. Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clin Infect Dis 2009;48:274-84.
9. Purcell K, Fergie J, Peterson MD. Economic impact of the community-acquired methicillin-resistant Staphylococcus aureus epidemic on the Driscoll Children's Health Plan. Pediatr Infect Dis J 2006;25:178-80. (Pubitemid 43208578)
10. Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005;165:1756-61. (Pubitemid 41138964)
11. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74.
12. Lee TC, Carrick MM, Scott BG, et al. Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital. Am J Surg 2007;194:809-12; discussion, 12-13.
13. Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillinresistant Staphylococcus aureus infection. Clin Infect Dis 2006;43:953-60. (Pubitemid 44631092)
14. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in los Angeles. N Engl J Med 2005;352:1445-53. (Pubitemid 40471452)
15. Wright CT, Stocks RM, Armstrong DL, et al. Pediatric mediastinitis as a complication of methicillin-resistant Staphylococcus aureus retropharyngeal abscess. Arch Otolaryngol Head Neck Surg 2008;134:408-13. (Pubitemid 351581089)
16. Gonzalez BE, Teruya J, Mahoney DH Jr., et al. Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics 2006;117:1673-9. (Pubitemid 46071396)
17. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:100-7. (Pubitemid 40053465)
18. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12:894-9. (Pubitemid 43848409)
19. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007;56:325-9.
20. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005;41:583-90. (Pubitemid 41170343)
21. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 2008;122:805-11.
22. Arnold SR, Elias D, Buckingham SC, et al. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J Pediatr Orthop 2006;26:703-8. (Pubitemid 44655534)
23. Crary SE, Buchanan GR, Drake CE, et al. Venous thrombosis and thromboembolism in children with osteomyelitis. J Pediatr 2006;149:537-41. (Pubitemid 44441416)
24. Rutar T, Chambers HF, Crawford JB, et al. Ophthalmic manifestations of infections caused by the USA300 clone of communityassociated methicillin-resistant Staphylococcus aureus. Ophthalmology 2006;113:1455-62. (Pubitemid 44108175)
25. Kravitz GR, Dries DJ, Peterson ML, et al. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005;40:941-7. (Pubitemid 40418298)
26. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005;353:1245-51. (Pubitemid 41345946)
27. Field MJ, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on clinical practice guidelines, clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990;52-77.
28. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979;121:1193-254.
29. Martinez-Aguilar G, Hammerman WA, Mason EO Jr., et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22:593-8. (Pubitemid 36900204)
30. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002;21:530-4. (Pubitemid 34625834)
31. Marcinak JF, Frank AL. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis 2003;16:265-9. (Pubitemid 36677323)
32. Nicholas P, Meyers BR, Levy RN, et al. Concentration of clindamycin in human bone. Antimicrob Agents Chemother 1975;8:220-1.
33. Joiner KA, Lowe BR, Dzink JL, et al. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J Infect Dis 1981;143:487-94. (Pubitemid 11113671)
34. Panzer JD, Brown DC, Epstein WL, et al. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol New Drugs 1972;12:259-62.
35. Tsuji BT, Rybak MJ, Cheung CM, et al. Community-and health careassociated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis 2007;58:41-7. (Pubitemid 46694261)
36. Hulten KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated Staphylococcus aureus infections in children. Pediatr Infect Dis J 2006;25:349-53.
37. Chavez-Bueno S, Bozdogan B, Katz K, et al. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 2005;49:2283-8. (Pubitemid 40734455)
38. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians microbiologists be concerned? Clin Infect Dis 2005;40:280-5. (Pubitemid 40110675)
39. Raveh D, Rabinowitz B, Breuer GS, et al. Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. Int J Antimicrob Agents 2006;28:231-7. (Pubitemid 44223986)
40. Steele RW, Russo TM, Thomas MP. Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children. Clin Pediatr (Phila) 2006;45:245-50. (Pubitemid 43788343)
41. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 2006;107:1120-38.
42. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-7. (Pubitemid 43224254)
43. Vikram HR, Havill NL, Koeth LM, et al. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005;43:5384-7. (Pubitemid 41484067)
44. Hayden MK, Rezai K, Hayes RA, et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43:5285-7. (Pubitemid 41484040)
45. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007;45:601-8. (Pubitemid 47328642)
46. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:2137-45. (Pubitemid 43807536)
47. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50:1581-5.
48. Patel JB, Jevitt LA, Hageman J, et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42:1652-3.
49. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
50. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81. (Pubitemid 38781657)
51. Miller BA, Gray A, Leblanc TW, et al. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 2010;50: e63-8.
52. Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008;27:330-4. (Pubitemid 351483068)
53. Howe RA, Wootton M, Noel AR, et al. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid. Antimicrob Agents Chemother 2003;47:3651-2. (Pubitemid 37345741)
54. Wootton M, Howe RA, Walsh TR, et al. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J Antimicrob Chemother 2002;50:760-1. (Pubitemid 35331701)
55. Bozdogan B, Esel D, Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003;52:864-8. (Pubitemid 37407819)
56. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4.
57. Pillai SK, Sakoulas G, Wennersten C, et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 2002;186:1603-7. (Pubitemid 35379637)
58. Arias CA, Vallejo M, Reyes J, et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008;46:892-6. (Pubitemid 351379975)
59. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007;64:1506-14. (Pubitemid 46889900)
60. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31. (Pubitemid 39077924)
61. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin Infect Dis 2002;34:1651-2. (Pubitemid 34615453)
62. Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003;22: S186-92.
63. Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003;22: S193-200. (Pubitemid 37158769)
64. Drew RH, Perfect JR, Srinath L, et al; for the Synercid Emergency-Use Study Group. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000;46:775-84.
65. Sander A, Beiderlinden M, Schmid EN, et al. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 2002;28:1157-60. (Pubitemid 34985243)
66. Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002;21:950-6. (Pubitemid 35176157)
67. Blaser J, Vergeres P, Widmer AF, et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 1995;39:1134-9.
68. Widmer AF, Frei R, Rajacic Z, et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990;162:96-102. (Pubitemid 20223955)
69. Zimmerli W, Frei R, Widmer AF, et al. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994;33:959-67. (Pubitemid 24170895)
70. Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992;29:719-24.
71. Euba G, Lora-Tamayo J, Murillo O, et al. Pilot study of ampicillinceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother 2009;53:4305-10.
72. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537-41. (Pubitemid 28233008)
73. Norden CW, Bryant R, Palmer D, et al. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51.
74. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111: e394-434.
75. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49:1908-14.
76. Ruhe JJ, Monson T, Bradsher RW, et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005;40:1429-34. (Pubitemid 40628630)
77. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006;44:108-18. (Pubitemid 43100588)
78. Bismuth R, Zilhao R, Sakamoto H, et al. Gene heterogeneity for tetracycline resistance in Staphylococcus spp. Antimicrob Agents Chemother 1990;34:1611-4. (Pubitemid 20257621)
79. Schwartz BS, Graber CJ, Diep BA, et al. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis 2009;48:1483-4.
80. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-9. (Pubitemid 44884142)
81. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44.
82. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84. (Pubitemid 37505530)
83. Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: summary of an experts' meeting covened by the Centers for Disease Control and Prevention, 2006. http://www.cdc.gov/ncidod/ dhqp/ar-mrsa-ca.html. Accessed 27 April 2009.
84. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:2628-30. (Pubitemid 47047353)
85. Szumowski JD, Cohen DE, Kanaya F, et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423-8. (Pubitemid 46185256)
86. Euba G, Murillo O, Fernandez-Sabe N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009;53:2672-6.
87. Sanchez C, Matamala A, Salavert M, et al. Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection. Enferm Infecc Microbiol Clin 1997;15:10-3. (Pubitemid 27094964)
88. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086-91. (Pubitemid 28553722)
89. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004;38:338-41. (Pubitemid 38112251)
90. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8.
91. Hyun DY, Mason EO, Forbes A, et al. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2009;28:57-9.
92. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole- induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010;170:1045-9.
93. Deresinski S. Counterpoint: vancomycin Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-8. (Pubitemid 46871499)
94. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45(Suppl 3): S191-5. (Pubitemid 47378906)
95. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402. (Pubitemid 38747480)
96. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72. (Pubitemid 39577670)
97. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31. (Pubitemid 20177385)
98. Stryjewski ME, Szczech LA, Benjamin DK Jr., et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysisdependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-6. (Pubitemid 46079979)
99. Chang FY, Peacock JE Jr., Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333-9. (Pubitemid 37229468)
100. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008;52:192-7.
101. Lodise TP Jr., McKinnon PS, Levine DP, et al. Impact of empiricaltherapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3731-3. (Pubitemid 47519366)
102. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988;32:1320-2.
103. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-6. (Pubitemid 23046569)
104. Cooper GL. Pharmacokinetics of vancomycin. Vancomycin: a comprehensive review of 30 years clinical experience. San Diego, CA: Park Row Publishers, 1986;23-8.
105. Albanese J, Leone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000;44:1356-8. (Pubitemid 30228320)
106. Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008;51:291-8.
107. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009;15:1516-8.
108. Fitch MT, Manthey DE, McGinnis HD, et al. Videos in clinical medicine. Abscess incision and drainage. N Engl J Med 2007;357: e20. (Pubitemid 350074690)
109. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406. (Pubitemid 41581713)
110. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by communityacquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-7. (Pubitemid 38222783)
111. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004;139:947-51; discussion, 51-53.
112. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007;51:4044-8. (Pubitemid 350057804)
113. Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010;56:283-7.
114. Duong M, Markwell S, Peter J, et al. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010;55:401-7.
115. Ruhe JJ, Smith N, Bradsher RW, et al. Community-onset methicillinresistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777-84. (Pubitemid 46365300)
116. Deleo FR, Otto M, Kreiswirth BN, et al. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010;375:1557-68.
117. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3298-303. (Pubitemid 350067543)
118. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005;159:980-5. (Pubitemid 41423339)
119. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42.
120. Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008;168:805-19. (Pubitemid 351620083)
121. d'Oliveira RE, Barros RR, Mendonca CR, et al. Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil. Microb Drug Resist 2003;9:87-91. (Pubitemid 36403062)
122. Libertin CR, Wold AD, Washington JA 2nd. Effects of trimethoprimsulfamethoxazole and incubation atmosphere on isolation of group A streptococci. J Clin Microbiol 1983;18:680-2. (Pubitemid 13004219)
123. Trickett PC, Dineen P, Mogabgab W. Clinical experience: respiratory tract. Trimethoprim-sulfamethoxazole versus penicillin G in the treatment of group A beta-hemolytic streptococcal pharyngitis tonsillitis. J Infect Dis 1973;128:693-5.
124. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007;45:1350-2. (Pubitemid 46626515)
125. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40:1785-91. (Pubitemid 40799948)
126. Tayal VS, Hasan N, Norton HJ, et al. The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department. Acad Emerg Med 2006;13:384-8.
127. Squire BT, Fox JC, Anderson C. ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections. Acad Emerg Med 2005;12:601-6. (Pubitemid 40827130)
128. Epperly TD. The value of needle aspiration in the management of cellulitis. J Fam Pract 1986;23:337-40. (Pubitemid 16004771)
129. Fleisher G, Ludwig S. Cellulitis: a prospective study. Ann Emerg Med 1980;9:246-9. (Pubitemid 10037703)
130. Fleisher G, Ludwig S, Campos J. Cellulitis: bacterial etiology, clinical features, and laboratory findings. J Pediatr 1980;97:591-3. (Pubitemid 11238444)
131. Lee PC, Turnidge J, McDonald PJ. Fine-needle aspiration biopsy in diagnosis of soft tissue infections. J Clin Microbiol 1985;22:80-3. (Pubitemid 15032677)
132. Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988;26:401-4. (Pubitemid 18062089)
133. Swartz MN. Clinical practice. Cellulitis N Engl J Med 2004;350:904-12.
134. Elliott DJ, Zaoutis TE, Troxel AB, et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillinresistant Staphylococcus aureus. Pediatrics 2009;123: e959-66.
135. Jeng A, Beheshti M, Li J, et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010;89:217-26.
136. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6. (Pubitemid 40734452)
137. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5): S341-53. (Pubitemid 41170381)
138. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-93. (Pubitemid 351706765)
139. Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003;22: S172-7. (Pubitemid 37158766)
140. Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of shortcourse (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669-74. (Pubitemid 39037946)
141. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:752-60. (Pubitemid 351321562)
142. Centers for Disease Control Prevention. Environmental cleaning & disinfecting for MRSA: what's the difference between cleaners, sanitizers, and disinfectants? 2010. http://www.cdc.gov/mrsa/environ-ment/index.html. Accessed 13 October 2010.
143. Robicsek A, Beaumont JL, Thomson RB Jr., et al. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol 2009;30:623-32.
144. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003;37:933-8. (Pubitemid 37267208)
145. van Rijen M, Bonten M, Wenzel R, et al. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008 Oct. 8; 4: CD006216.
146. Wertheim HF, Vos MC, Ott A, et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004;140:419-25.
147. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1412-6. (Pubitemid 29259335)
148. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010;362:9-17.
149. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996;156:1109-12. (Pubitemid 26158068)
150. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin- resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007;51:3591-8. (Pubitemid 47519348)
151. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrugresistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008;148:249-57. (Pubitemid 351665484)
152. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009;49:935-41.
153. Yang ES, Tan J, Eells S, et al. Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect 2010;16:425-31.
154. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillinresistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-75. (Pubitemid 40175973)
155. Nguyen DM, Mascola L, Brancoft E. Recurring methicillin-resistant Staphylococcus aureus infections in a football team. Emerg Infect Dis 2005;11:526-32. (Pubitemid 40462900)
156. Romano R, Lu D, Holtom P. Outbreak of community-acquired methicillin-resistant Staphylococcus aureus skin infections among a collegiate football team. J Athl Train 2006;41:141-5. (Pubitemid 43807208)
157. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007;44: e88-95.
158. Boubaker K, Diebold P, Blanc DS, et al. Panton-valentine leukocidin and staphyloccoccal skin infections in schoolchildren. Emerg Infect Dis 2004;10:121-4. (Pubitemid 38040703)
159. Whitman TJ, Herlihy RK, Schlett CD, et al. Chlorhexidineimpregnated cloths to prevent skin and soft-tissue infection in marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol 2010;12:1207-15.
160. American Academy of Pediatrics. Antibacterial Drugs for Newborn Infantsl. Pickering LK, Baker CJ, Kimberlin DW, Long SS eds: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009, p746.
161. Wendt C, Schinke S, Wurttemberger M, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillinresistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 2007;28:1036-43. (Pubitemid 47345262)
162. Hurwitz R. Atopic dermatitis. In: Hurwitz R, ed. Clinical pediatric dermatology. 2nd ed. Philadelphia, PA: W. B. Saunders, 1993;55-56.
163. Fisher RG, Chain RL, Hair PS, et al. Hypochlorite killing of community-associated methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2008;27:934-5.
164. Loeb M, Main C, Walker-Dilks C, et al. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003;4: CD003340.
165. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007;35:106-14. (Pubitemid 46283602)
166. Washington University School of Medicine. Staphylococcus aureus decolonization study (SuDS) (NCT00731783). http://clinical-trials.gov/ct2/show/ NCT00731783?id5NCT00731783&rank51. Accessed 13 October 2010.
167. Natividad Medical Center. A prospective trial of nasal mupirocin, hexachlorophene body Wash, systemic antibiotics for prevention of recurrent methicillin resistant staphylococcus aureus infections (NCT01049438). http://clinicaltrials.gov/ct2/show/NCT01049438?id=NCT01049438&rank=1. Accessed 13 October 2010.
168. Los Angeles Biomedical Research Institute. A randomized clinical trial to prevent recurrent CA-MRSA infection (PRIMO) (NCT00560599). http:// clinicaltrials.gov/ct2/show/NCT00560599?id=NCT00560599&rank=1. Accessed 13 October 2010.
169. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007;44:178-85. (Pubitemid 46079977)
170. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005;41:507-14. (Pubitemid 41099645)
171. Fowler VG Jr., Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005;293:3012-21. (Pubitemid 40965071)
172. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
173. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2463-7. (Pubitemid 351915676)
174. Cosgrove SE, Vigliani GA, Fowler VG Jr., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48:713-21.
175. Karchmer AW, Archer GL, Dismukes WE. Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983;5(Suppl 3): S543-8.
176. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983;98:447-55. (Pubitemid 13116611)
177. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of highdose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80.
178. Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. (Pubitemid 44527494)
179. Rose WE, Leonard SN, Sakoulas G, et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:831-6. (Pubitemid 351358359)
180. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007;60:334-40. (Pubitemid 47243883)
181. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:3061-7.
182. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52. (Pubitemid 40800587)
183. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008;62:1413-21.
184. Ardura MI, Mejias A, Katz KS, et al. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26:1128-32. (Pubitemid 350190945)
185. Chandorkar G, Abdle-Rahman S, Jacobs R, et al. Pharmacokinetics (PK) and safety of 8 and 10 mg/kg of daptomycin in pediatric patients aged 2 to 6 years. [abstract number 1243]. In: Program and abstracts of the 47th annual meeting of the Infectious Diseases Society of America. Philadelphia, PA: Infectious Diseases Society of America, 2009.
186. Boucher H, Corey G, Filler S, et al. Appropriateness of two-week therapy for catheter-related S. aureus bacteremia [abstract number L-1204]. In: Program and abstracts of the 46th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, 2006.
187. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993;119:304-11. (Pubitemid 23319889)
188. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46(Suppl 5): S386-93. (Pubitemid 351717326)
189. Dworkin RJ, Lee BL, Sande MA, et al. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989;2:1071-3. (Pubitemid 19264078)
190. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996;101:68-76. (Pubitemid 26285943)
191. Fowler VG Jr., Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997;30:1072-8. (Pubitemid 27435904)
192. Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005;14:23-8. (Pubitemid 47050764)
193. Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia. Am Heart J 2004;147:536-9. (Pubitemid 38880879)
194. Reynolds HR, Jagen MA, Tunick PA, et al. Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era. J Am Soc Echocardiogr 2003;16:67-70. (Pubitemid 36522818)
195. Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005;115: e15-9. (Pubitemid 43046258)
196. Fowler VG Jr., Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998;27:478-86. (Pubitemid 28421994)
197. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001;104:1029-33. (Pubitemid 32803880)
198. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-77.
199. Vikram HR, Buenconsejo J, Hasbun R, et al. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA 2003;290:3207-14. (Pubitemid 38020682)
200. D'Agostino RS, Miller DC, Stinson EB, et al. Valve replacement in patients with native valve endocarditis: what really determines operative outcome? Ann Thorac Surg 1985;40:429-38. (Pubitemid 16223244)
201. Mullany CJ, McIsaacs AI, Rowe MH, et al. The surgical treatment of infective endocarditis. World J Surg 1989;13:132-6; discussion, 36. (Pubitemid 19043582)
202. John MD, Hibberd PL, Karchmer AW, et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998;26:1302-9.
203. Bishara J, Leibovici L, Gartman-Israel D, et al. Long-term outcome of infective endocarditis: the impact of early surgical intervention. Clin Infect Dis 2001;33:1636-43. (Pubitemid 33044526)
204. Remadi JP, Habib G, Nadji G, et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg 2007;83:1295-302. (Pubitemid 46440736)
205. Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010;138:130-6.
206. Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004;170:786-92. (Pubitemid 39298995)
207. Shorr AF, Combes A, Kollef MH, et al. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006;34:700-6.
208. Zahar JR, Clec'h C, Tafflet M, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005;41:1224-31. (Pubitemid 41532663)
209. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-9. (Pubitemid 26413723)
210. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010;38:175-80.
211. Conte JE Jr., Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80. (Pubitemid 34415331)
212. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12. (Pubitemid 32173626)
213. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92. (Pubitemid 36459702)
214. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97. (Pubitemid 37433574)
215. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008;134:1200-7.
216. Kimura A, Mochizuki T, Nishizawa K, et al. Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J Trauma 1998;45:383-7. (Pubitemid 28399736)
217. Mathews CJ, Coakley G. Septic arthritis: current diagnostic and therapeutic algorithm. Curr Opin Rheumatol 2008;20:457-62.
218. Sia IG, Berbari EF. Infection and musculoskelet al. conditions: osteomyelitis. Best Pract Res Clin Rheumatol 2006;20:1065-81.
219. Darley ES, MacGowan AP. Antibiotic treatment of grampositive bone and joint infections. J Antimicrob Chemother 2004;53:928-35. (Pubitemid 38811422)
220. Stengel D, Bauwens K, Sehouli J, et al. Systematic review and metaanalysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001;1:175-88. (Pubitemid 33586051)
221. Daver NG, Shelburne SA, Atmar RL, et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007;54:539-44. (Pubitemid 46731229)
222. Dombrowski JC, Winston LG. Clinical failures of appropriatelytreated methicillin-resistant Staphylococcus aureus infections. J Infect 2008;57:110-5.
223. Al-Nammari SS, Lucas JD, Lam KS. Hematogenous methicillin-resistant Staphylococcus aureus spondylodiscitis. Spine (Phila Pa 1976) 2007;32:2480-6. (Pubitemid 350303696)
224. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003;114:723-8. (Pubitemid 36776353)
225. Van der Auwera P, Klastersky J, Thys JP, et al. Double-blind, placebocontrolled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985;28:467-72. (Pubitemid 16236531)
226. Priest DH, Peacock JE Jr. Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes. South Med J 2005;98:854-62. (Pubitemid 41396080)
227. Livorsi DJ, Daver NG, Atmar RL, et al. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 2008;57:128-31.
228. Crompton JA, North DS, McConnell SA, et al. Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J Chemother 2009;21:414-20.
229. Lamp KC, Friedrich LV, Mendez-Vigo L, et al. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007;120: S13-20. (Pubitemid 47464123)
230. Shipton LK, Pillai S, Gold H, et al. Experience with daptomycin in Staphylococcus bone and joint infections: case series and emergence of nonsusceptibility. Infect Dis Clin Pract 2007;15:324-29. (Pubitemid 47415197)
231. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6. (Pubitemid 43222276)
232. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Communityacquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskelet al. infections in children. Pediatr Infect Dis J 2004;23:701-6. (Pubitemid 39063283)
233. Broder KW, Moise PA, Schultz RO, et al. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann Plast Surg 2004;52:385-90. (Pubitemid 38500359)
234. Chen CJ, Chiu CH, Lin TY, et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007;26:985-8.
235. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8. (Pubitemid 38250962)
236. Rao N, Hamilton CW. Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007;59:173-9. (Pubitemid 47484126)
237. Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004;32:8-14. (Pubitemid 38210506)
238. Jensen AG, Espersen F, Skinhoj P, et al. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med 1998;158:509-17. (Pubitemid 128681612)
239. Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival. J Bone Joint Surg Br 2001;83:403-7.
240. Barberan J, Aguilar L, Carroquino G, et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 2006;119: e7-10.
241. Aboltins CA, Page MA, Buising KL, et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007;13:586-91. (Pubitemid 46730664)
242. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-54.
243. Kowalski TJ, Berbari EF, Huddleston PM, et al. The management and outcome of spinal implant infections: contemporary retrospective cohort study. Clin Infect Dis 2007;44:913-20. (Pubitemid 46452054)
244. Zalavras CG, Christensen T, Rigopoulos N, et al. Infection following operative treatment of ankle fractures. Clin Orthop Relat Res 2009;467:1715-20.
245. Carrillo-Marquez MA, Hulten KG, Hammerman W, et al. USA-300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. Pediatr Infect Dis J 2009;28:1076-80.
246. Peltola H, Paakkonen M, Kallio P, et al. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis 2009;48:1201-10.
247. Ballock RT, Newton PO, Evans SJ, et al. A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis. J Pediatr Orthop 2009;29:636-42.
248. Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003;98:1040-4. (Pubitemid 36460895)
249. Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007;43:449-55. (Pubitemid 350085281)
250. Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol 2008;69:126-9; discussion, 29. (Pubitemid 351186724)
251. Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006;50:3971-6. (Pubitemid 44865137)
252. Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007;51:379-82. (Pubitemid 46047736)
253. Nagashima G, Okamoto N, Okuda M, et al. Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother 2008;14:147-50. (Pubitemid 351624457)
254. Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984;26:811-4. (Pubitemid 15181369)
255. Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984;100:881-90. (Pubitemid 14121606)
256. Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006;57:720-3.
257. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004;48:3928-33. (Pubitemid 39304623)
258. Lu CH, Chang WN. Adults with meningitis caused by oxacillin-resistant Staphylococcus aureus. Clin Infect Dis 2000;31:723-7.
259. Chang WN, Lu CH, Wu JJ, et al. Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillinresistant and methicillin-sensitive strains. Infection 2001;29:245-50. (Pubitemid 32929628)
260. von Specht M, Gardella N, Tagliaferri P, et al. Methicillin-resistant Staphylococcus aureus in community-acquired meningitis. Eur J Clin Microbiol Infect Dis 2006;25:267-9. (Pubitemid 43800548)
261. Dylewski J, Martel G. A case of spontaneous methicillin-resistant Staphylococcus aureus meningitis in a health care worker. Can J Infect Dis Med Microbiol 2004;15:336-8. (Pubitemid 40065302)
262. Pintado V, Meseguer MA, Fortun J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002;21:864-8. (Pubitemid 36160712)
263. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6. (Pubitemid 351521995)
264. Gallagher RM, Pizer B, Ellison JA, et al. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008;57:410-3.
265. Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007;35:271-4. (Pubitemid 47222278)
266. Naesens R, Ronsyn M, Druwe P, et al. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 2009;58:1247-51.
267. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007;41:296-308. (Pubitemid 46340060)
268. Vartzelis G, Theodoridou M, Daikos GL, et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005;33:36-8. (Pubitemid 40585499)
269. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008;47:588-90.
270. Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002;21:632-6. (Pubitemid 34761443)
271. Whitehead WE, Kestle JR. The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons. Pediatr Neurosurg 2001;35:205-10. (Pubitemid 33033435)
272. Sacar S, Turgut H, Toprak S, et al. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006;6:43.
273. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010;362:146-54.
274. Brown EM, Edwards RJ, Pople IK. Conservative management of patients with cerebrospinal fluid shunt infections. Neurosurgery 2006;58:657-65; discussion, 57-65.
275. Amod F, Moodley I, Peer AK, et al. Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin. J Infect 2005;50:252-7. (Pubitemid 40361539)
276. Elvy J, Porter D, Brown E. Treatment of external ventricular drainassociated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008;61:461-2.
277. Southwick FS, Richardson EP Jr., Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore) 1986;65:82-106. (Pubitemid 16099669)
278. Bhatia K, Jones NS. Septic cavernous sinus thrombosis secondary to sinusitis: are anticoagulants indicated? A review of the literature. J Laryngol Otol 2002;116:667-76. (Pubitemid 34994955)
279. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-11. (Pubitemid 46080052)
280. Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxicshock syndrome-associated exotoxin production. J Infect Dis 1984;149:471. (Pubitemid 14138254)
281. Stevens DL, Wallace RJ, Hamilton SM, et al. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006;42:729-30. (Pubitemid 43271393)
282. Bernardo K, Pakulat N, Fleer S, et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004;48:546-55. (Pubitemid 38141715)
283. Ho JL, Klempner MS. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis 1986;4:133-8. (Pubitemid 16036592)
284. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by timekill curve methods. J Antimicrob Chemother 2003;51:857-64. (Pubitemid 36503419)
285. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:418-20. (Pubitemid 36070400)
286. Booker BM, Stahl L, Smith PF. In vitro antagonism with the combination of vancomycin and clindamycin against Staphylococcus aureus. J Appl Res 2004;4:385-95. (Pubitemid 39299383)
287. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3002-4. (Pubitemid 37040287)
288. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005;128:2732-8. (Pubitemid 41507634)
289. Yanagisawa C, Hanaki H, Natae T, et al. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother 2007;13:368-72. (Pubitemid 350308154)
290. Darenberg J, Soderquist B, Normark BH, et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004;38:836-42. (Pubitemid 38387232)
291. Brown EL, Bowden MG, Bryson RS, et al. Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin. Clin Vaccine Immunol 2009;16:139-41.
292. Yoong P, Pier GB. Antibody-mediated enhancement of communityacquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A 2010;107:2241-6.
293. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004;39:38-46. (Pubitemid 38879547)
294. Kreymann KG, de Heer G, Nierhaus A, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85. (Pubitemid 350175761)
295. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:2686-92. (Pubitemid 350175762)
296. Turgeon AF, Hutton B, Fergusson DA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203. (Pubitemid 351650633)
297. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
298. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536-42. (Pubitemid 46871498)
299. Mohammedi I, Descloux E, Argaud L, et al. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. Int J Antimicrob Agents 2006;27:259-62. (Pubitemid 43246959)
300. Wang JT, Fang CT, Chen YC, et al. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001;47:246.
301. James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40:696-700. (Pubitemid 26071537)
302. Lacy MK, Tessier PR, Nicolau DP, et al. Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci. Int J Antimicrob Agents 2000;15:25-30. (Pubitemid 30336367)
303. Wysocki M, Thomas F, Wolff MA, et al. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother 1995;35:352-4.
304. Ebert SL, Craig W. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and resistant S. aureus [abstract 439]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemother. New York, 1987.
305. Dudley MD, Griffith E, Corcoran C, et al. Pharmacokineticpharmacodynamic indices for vancomycin treatment of susceptible intermediate S. aureus in the neutropenic murine thigh model [abstract 2031]. In: Program and Abstracts of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999.
306. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57(Suppl 2): S4-9.
307. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42. (Pubitemid 39447034)
308. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55. (Pubitemid 44583720)
309. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51. (Pubitemid 38200128)
310. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20.
311. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44. (Pubitemid 44631403)
312. Maor Y, Hagin M, Belausov N, et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009;199:619-24.
313. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-5. (Pubitemid 40331152)
314. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a doubleblind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66. (Pubitemid 41552597)
315. Lee-Such SC, Overholser BR, Munoz-Price LS. Nephrotoxicity associated with aggressive vancomycin therapy [abstract #1298]. In: Program and abstracts of the 46th annual meeting of the Interscience Conference on antimicrobial agents Chemotherapy. San Francisco, CA: 2006.
316. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-15. (Pubitemid 47208584)
317. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009;53:483-6.
318. Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402.
319. Odio C, McCracken GH Jr., Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984;105:491-3. (Pubitemid 14072144)
320. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-39. (Pubitemid 36241308)
321. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003;47:1262-6. (Pubitemid 36368583)
322. Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001;39:2439-44. (Pubitemid 32606216)
323. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003;47:3040-5. (Pubitemid 37229554)
324. Tenover FC, Sinner SW, Segal RE, et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009;33:564-8.
325. Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001;47:399-403. (Pubitemid 32303403)
326. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-15. (Pubitemid 46651246)
327. Wootton M, MacGowan AP, Walsh TR, et al. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007;45:329-32.
328. Yusof A, Engelhardt A, Karlsson A, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol 2008;46:3042-7.
329. Leonard SN, Rossi KL, Newton KL, et al. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009;63:489-92.
330. Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009;47:2013-7.
331. Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6. (Pubitemid 44737223)
332. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007;60:788-94. (Pubitemid 47434257)
333. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5. (Pubitemid 38781661)
334. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200. (Pubitemid 351269157)
335. Alos JI, Garcia-Canas A, Garcia-Hierro P, et al. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008;62:773-5.
336. Holmes RL, Jorgensen JH. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008;52:757-60. (Pubitemid 351170860)
337. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006;42(Suppl 1): S13-24. (Pubitemid 41832061)
338. Sader HS, Fey PD, Fish DN, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillinresistant Staphylococcus aureus isolates collected in nine U. S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009;53:4127-32.
339. Wikler MA, Low DE, Cockerill FR, et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-seventh edition. CLSI (formerly NCCLS), 2006; M7-A7.
340. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008;52:4528.
341. Mason EO, Lamberth LB, Hammerman WA, et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. Journal of Clinical Microbiology 2009;47:1682-30.
342. Hawkins C, Huang J, Jin N, et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007;167:1861-7. (Pubitemid 47481481)
343. Smith PF, Booker BM, Ogundele AB, et al. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis 2005;52:255-9. (Pubitemid 41133552)
344. Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003;47:3960-3. (Pubitemid 37485015)
345. Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90.
346. Pillai SK, Gold HS, Sakoulas G, et al. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 2007;51:2223-5. (Pubitemid 46903123)
347. Cui L, Tominaga E, Neoh HM, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycinintermediate staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1079-82. (Pubitemid 43327815)
348. Hirschwerk D, Ginocchio CC, Bythrow M, et al. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2006;27:315-7.
349. Kullar R, Davis S, Levine D, et al. High-dose daptomycin for complicated gram-positive infections [poster # 1984]. Helsinki, Finland: European Congress of Clinical Microbiology and Infectious Diseases, 2009.
350. Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007;51:1504-7. (Pubitemid 46586838)
351. Baltch AL, Ritz WJ, Bopp LH, et al. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable smallcolony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother 2008;52:1829-33. (Pubitemid 351614679)
352. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005;49:2735-45. (Pubitemid 40917586)
353. Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:1714-8. (Pubitemid 36548559)
354. Miro JM, Garcia-de-la-Maria C, Armero Y, et al. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4172-7.
355. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-55. (Pubitemid 29331226)
356. Proctor RA. Role of folate antagonists in the treatment of methicillinresistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:584-93. (Pubitemid 351263501)
357. Schwalm JD, El-Helou P, Lee CH. Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment. Can J Infect Dis 2004;15:97-100. (Pubitemid 38667761)
358. Munoz P, Rodriguez-Creixems M, Moreno M, et al. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007;13:211-5. (Pubitemid 46111620)
359. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006;58:273-80. (Pubitemid 44313381)
360. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009;49:395-401.
361. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid rifampin. Pharmacotherapy 2007;27:476-9. (Pubitemid 46327916)
362. Egle H, Trittler R, Kummerer K, et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005;77:451-3. (Pubitemid 40719273)
363. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2010 Apr. 6. [Epub ahead of print].
364. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010;65:1315-6.
365. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999;43:1747-53. (Pubitemid 29331259)
366. Fox PM, Lampen RJ, Stumpf KS, et al. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and bet al.actam antibiotics. Antimicrob Agents Chemother 2006;50:2951-6. (Pubitemid 44396397)
367. Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 2010;54:3161-9.
368. Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007;120:937-45. (Pubitemid 350085525)
369. Tan TQ, Mason EO Jr., Ou CN, et al. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993;37:2401-6. (Pubitemid 23324463)
370. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003;22: S158-63.
371. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents and Chemother 2010;54:5187-92.